9 April 2024 - This article describes how CMS’s approach to implementing the negotiations will be shaped by the distinctive features of the selected drugs in this first round. 

Recommendations to CMS are made in the hope of advancing the program’s predictability and reliability while minimising the risk of unintended consequences. This is particularly important for encouraging investment in comparative effectiveness evidence relevant to Medicare beneficiaries, and potentially in new drugs and drug categories.

Read Health Affairs article